多肾移植受者非黑色素瘤皮肤癌发病率随治疗模式变化
该回顾性分析基于爱尔兰国家肾移植服务数据库与癌症登记数据(1994-2014),纳入3821例肾移植受者。提示移植失败期NMSC风险仍残留升高,需持续癌症监测。
要点
- 移植肾功能正常期NMSC发病率是移植失败期的2.19倍(aIRR 2.19,95%CI 1.56-3.07)。
- 首次移植后透析期NMSC发病率降至19.29/1000患者年(95%CI 13.41-27.76)。
- 每次后续移植后NMSC发病率均呈现相似的升降模式。
核心结论
- 多肾移植受者中,移植失败期NMSC发病率下降但仍有残留风险升高。
- 总体浸润性癌症发病率停滞,强调移植失败期需持续癌症监测。
研究设计与样本
- 回顾性分析爱尔兰国家肾移植服务数据库与爱尔兰癌症登记数据(1994-2014)。
- 纳入3821例肾移植受者,其中3215例接受1次移植,522例接受2次,84例接受3次及以上。
- 使用爱尔兰人口普查数据计算标准化发病率比(SIR),采用泊松回归计算发病率与率比。
主要发现
- 首次移植后透析期NMSC的aIRR为19.29/1000患者年(95%CI 13.41-27.76),低于首次移植期的41.7/1000患者年(95%CI 39.38-44.15)。
- 每次后续连续移植后NMSC发病率均呈现相似的升降模式。
临床怎么用
- 肾移植受者即使移植失败返回透析,仍应继续皮肤癌监测。
- 多肾移植受者需关注NMSC风险随治疗模式变化的动态评估。
局限性
- 可能存在 ascertainment bias(确认偏倚)影响观察趋势。
- 回顾性设计可能限制因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Existing data suggest that nonmelanoma skin cancer (NMSC) is more common in renal transplant recipients than in maintenance dialysis patients. However, whether the risk of NMSC varies as the treatment modality for end-stage kidney disease (ESKD) changes between dialysis and transplantation is not well described. OBJECTIVE: To determine whether the incidence of NMSC is attenuated during periods of graft loss with a return to dialysis in those who receive multiple kidney transplants. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of data from recipients of kidney transplants from the Irish National Kidney Transplant Service database, linked with the Irish Cancer Registry, from 1994 to 2014. All analysis took place between January 10, 2018 and March 31, 2018. Standardized incidence ratios (SIRs) were calculated for NMSC incidence in comparison with the general population using Irish census data as the denominator. Incidence of NMSC was calculated with modality of treatment for ESKD varying over time; incidence rates and rate ratios associated with dialysis intervals were calculated using Poisson regression; and disease was defined according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes for cancer diagnosis. EXPOSURES: Kidney transplantation. MAIN OUTCOMES AND MEASURES: Incidence rates per 1000 patient-years and incident rate ratios of NMSC after kidney transplant. RESULTS: Data from the records of 3821 deceased or living donor kidney transplant recipients were assessed; 2399 (62.8%) male and 1422 (37.2%) female recipients; mean (SD) age at time of first data recorded, 41.9 (16.0) years. A total of 3433 recipients were included who had a functioning transplant on January 1, 1994, or received a transplant after that date up to December 31, 2014: 3215 received 1 transplant, 522 a second kidney transplant, and 84 had 3 or more kidney transplants. Periods of treatment with a functioning transplant were associated with a higher incidence of NMSC diagnosis than periods of graft failure: adjusted incidence rate ratio (aIRR), 2.19 (95% CI, 1.56-3.07), P < .001. The aIRRs of NMSC fell from 41.7 (95% CI, 39.38-44.15) per 1000 patient-years in the first transplant to 19.29 (95% CI, 13.41-27.76) in the dialysis period following the first allograft failure. Incidence similarly rose and fell following each subsequent consecutive transplant. CONCLUSIONS AND RELEVANCE: In recipients of multiple kidney transplants, while the incidence of NMSC fell during periods defined by transplant failure, there was residual elevated risk. While ascertainment bias may have contributed to the observed trends, the stagnant incidence of invasive cancer overall highlights the need for continued cancer surveillance during graft failure.
引用
- Sexton DJ, O'Kelly P, O'Leary E, et al. Variation in Nonmelanoma Skin Cancer Incidence by Treatment Modality Among Patients Receiving Multiple Kidney Transplants. JAMA Dermatol. 2019. PMID: 30725084. doi:10.1001/jamadermatol.2018.4660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。